First published 9/28/2026, 5:37:15 AM · Last updated 9/28/2026, 5:37:30 AM

Biocontrol potential and genomic analysis of novel lytic bacteriophage CABI-SEA 2302 against multidrug-resistant avian pathogenic Escherichia coli associated with colibacillosis

Journal article (Elsevier) reporting genomic analysis and assessment of biocontrol potential of bacteriophage CABI-SEA 2302 against multidrug-resistant avian pathogenic Escherichia coli linked to colibacillosis. The supplied fields include no additional experimental details, results, or location information.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 4/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article addresses a potential biocontrol approach targeting multidrug-resistant avian pathogenic E. coli.

Sources

Biocontrol potential and genomic analysis of novel lytic bacteriophage CABI-SEA 2302 against multidrug-resistant avian pathogenic Escherichia coli associated with colibacillosis

Report an issue